Beta-containing COVID-19 booster vaccine found to cross-neutralize variants in non-human primates
A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Role of the humoral immune response during COVID-19: guilty or not guilty? - Mucosal Immunology
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection, Journal of Biomedical Science
Frontiers Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
Resources for Health Professionals
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection, Journal of Biomedical Science
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
Frontiers Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants, Journal of Biomedical Science
